Pet Diabetes Care Market Report 2026

Pet Diabetes Care Market Overview

• Pet Diabetes Care market size has reached to $2.4 billion in 2025 • Expected to grow to $3.8 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Surging Pet Insurance Adoption Catalyst For Growth In The Pet Diabetes Care Market • Market Trend: Universal Biosensors Unveils Petrackr Diabetes Monitoring Device • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pet Diabetes Care Market?

Pet diabetes care is used to treat pets suffering from diabetes, which may also cause other diseases such as heart disease, pancreatitis, urinary tract infections, kidney disease, and skin infections. Diabetes develops when a pet's body produces insufficient insulin, stops generating it altogether, or uses it improperly, which hinders the body from converting food into energy. The main drug type of pet diabetes care includes insulin therapy and oral medication. Insulin therapy is used to increase peripheral glucose intake while decreasing hepatic glucose synthesis in order to lower blood glucose levels in pets. The type of devices used for pet diabetes care include glucose monitoring devices and insulin delivery devices. The type of animals needing pet diabetes care are canine, feline and other animal types and used in veterinary clinics, home care settings and veterinary hospitals.

What Is The Pet Diabetes Care Market Growth Forecast?

The pet diabetes care market size is expected to see strong growth in the next few years. It will grow to $3.8 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to development of smart insulin delivery devices, expansion of home-based monitoring solutions, rising adoption of telemedicine platforms, increasing investment in veterinary endocrinology research, growing availability of species-specific oral medications. Major trends in the forecast period include increasing adoption of insulin therapy in pets, growth of at-home glucose monitoring for animals, rising awareness of diabetes management in companion animals, integration of telemedicine for pet diabetes care, development of species-specific oral hypoglycemic drugs.

Global Pet Diabetes Care Market Segmentation

1) By Drug Type: Insulin Therapy, Oral Medication 2) By Device Type: Glucose Monitoring Devices, Insulin Delivery Devices 3) By Animal Type: Canine, Feline, Other Animal Types 4) By End-User: Veterinary Clinics, Home Care Settings, Veterinary Hospitals Subsegments: 1) By Insulin Therapy: Canine Insulin Products, Feline Insulin Products, Insulin Delivery Devices 2) By Oral Medication: Glipizide, Metformin

What Is The Driver Of The Pet Diabetes Care Market?

The growing demand for pet insurance is anticipated to drive the growth of the pet diabetes care market going forward. Pet insurance is a type of financial protection that covers some of the veterinary costs associated with caring for pets and helps pet owners manage expenses related to their healthcare needs. Pet insurance is rising because veterinary treatment costs are increasing, making owners seek financial protection to manage unexpected medical expenses and ensure timely care for their pets. Pet diabetes care helps pet insurance by enabling early diagnosis and continuous management that reduces emergency complications and high treatment costs, supporting more predictable and sustainable insurance claims. For instance, in April 2025, according to the North American Pet Health Insurance Association (NAPHIA), a US based pet health insurance trade body, the number of insured pets in North America rose to 7.0 million in 2024, up from 6.25 million in 2023 (a 12.2% increase), highlighting rapidly growing demand for pet insurance as owners seek financial protection against rising veterinary costs. Therefore, the growing demand for pet insurance is driving the growth of the pet diabetes care industry.

Key Players In The Global Pet Diabetes Care Market

Major companies operating in the pet diabetes care market are C.H. Boehringer Sohn AG & Co. KG, Becton Dickinson and Company, Merck & Co Inc., Zoetis Inc., Trividia Health Inc., Allison Medical Inc., UltiMed Inc., Apotex Inc., Henry Schein VET GmbH, Medtrust Holdings Inc., i-SENS Inc., Taidoc Technology Corp., Covetrus Inc., ALR Technologies Inc., Vet Innovations Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, AgaMatrix Inc., Ascensia Diabetes Care Holdings AG, Bayer AG, Dexcom Inc., LifeScan Inc., Medtronic PLC, Novo Nordisk A/S, Sanofi S.A., Senseonics Holdings Inc., Tandem Diabetes Care Inc., Terumo Corporation, Animas Corporation, Insulet Corporation, Roche Diabetes Care Inc.

Global Pet Diabetes Care Market Trends and Insights

Major companies operating in the pet diabetes care market are focusing on innovating technological products, such as the Petrackr diabetes monitoring device, to provide reliable services to customers. Petrackr diabetes monitoring device is a veterinary blood glucometer designed to monitor diabetes in cats and dogs. For instance, in May 2023, Universal Biosensors Inc., an Australia -based biosensor company launched Petrackr diabetes monitoring device. Petrackr diabetes monitoring device delivers blood glucose test results in just seconds and easy to use for pet parents and veterinary clinicians. it is compatible with the Petrackr app, which allows users to easily record, monitor, and report results.

What Are Latest Mergers And Acquisitions In The Pet Diabetes Care Market?

In July 2024, Dechra Limited, a UK-based global veterinary pharmaceuticals and animal health company providing the rapeutic products and services for companion and food producing animals, acquired the long acting veterinary insulin programs from Akston Biosciences Corporation for an undisclosed amount. With this acquisition, Dechra expanded its portfolio of pet diabetes care solutions by securing the intellectual property and development rights to advanced insulin therapies designed to improve glucose management in diabetic dogs and cats, thereby strengthening its position in companion animal metabolic disease treatment and future product commercialization. Akston Biosciences Corporation is a US-based biotherapeutics company with developmental programs focused on innovative long acting insulin therapies for canine and feline diabetes.

Regional Outlook

North America was the largest region in the pet diabetes care market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Pet Diabetes Care Market?

The pet diabetes care market includes revenues earned by entities by insulin therapy and insulin delivery devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.